CD8A and neoplasm: The above findings suggested that the combination of CAR-Ms and the tumor-associated antigen NY-ESO1-expressing tumor cells led to more robust activation of anti-NY-ESO-1 CD8+ T cells than the CAR-Ms alone or tumor cells alone.